Nalaganje...

Correction: Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Immunother Cancer
Format: Artigo
Jezik:Inglês
Izdano: BMJ Publishing Group 2021
Teme:
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7883864/
https://ncbi.nlm.nih.gov/pubmed/33579740
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001622corr1
Oznake: Označite
Brez oznak, prvi označite!